Patents by Inventor Benjamin J. Umlauf

Benjamin J. Umlauf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240018263
    Abstract: The present invention provides antibodies that target glioblastoma stem-like cells and methods and kits for their use.
    Type: Application
    Filed: September 7, 2023
    Publication date: January 18, 2024
    Inventors: Michael Zorniak, Paul A. Clark, Yongku Peter Cho, Benjamin J. Umlauf, Eric V. Shusta, John Shu-Shin Kuo
  • Patent number: 11780932
    Abstract: The present invention provides antibodies that target glioblastoma stem-like cells and methods and kits for their use.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: October 10, 2023
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Michael Zorniak, Paul A. Clark, Yongku Peter Cho, Benjamin J. Umlauf, Eric V. Shusta, John Shu-Shin Kuo
  • Patent number: 10925960
    Abstract: A minimal antigen delivery system consists essentially of PEGylated stealth liposomes loaded with an immunogenic human leukocyte antigen (HLA) class restricted peptide and surface modified with a cell targeting peptide which mediates binding and internalization of the liposomes into a target cell.
    Type: Grant
    Filed: June 17, 2017
    Date of Patent: February 23, 2021
    Assignee: SRI INTERNATIONAL
    Inventors: Kathlynn C. Brown, Benjamin J. Umlauf
  • Publication number: 20200354472
    Abstract: The present invention provides antibodies that target glioblastoma stem-like cells and methods and kits for their use.
    Type: Application
    Filed: October 9, 2018
    Publication date: November 12, 2020
    Applicant: Wisconsin Alumni Research Foundation
    Inventors: Michael Zorniak, Paul A. Clark, Yongku Peter Cho, Benjamin J. Umlauf, Eric V. Shusta, John Shu-Shin Kuo
  • Publication number: 20170281752
    Abstract: A minimal antigen delivery system consists essentially of PEGylated stealth liposomes loaded with an immunogenic human leukocyte antigen (HLA) class restricted peptide and surface modified with a cell targeting peptide which mediates binding and internalization of the liposomes into a target cell.
    Type: Application
    Filed: June 17, 2017
    Publication date: October 5, 2017
    Applicant: SRI INTERNATIONAL
    Inventors: Kathlynn C. Brown, Benjamin J. Umlauf